Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.

Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

RenovoRx, Inc.

Country	United States
Founded	2012
IPO Date	Aug 26, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	17
CEO	Shaun Bagai

Contact Details

Address: 2570 West El Camino Real, Suite 320 Mountain View, California 94040 United States
Phone	650 284 4433
Website	renovorx.com

Stock Details

Ticker Symbol	RNXT
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$9.00
CIK Code	1574094
CUSIP Number	75989R107
ISIN Number	US75989R1077
Employer ID	27-1448452
SIC Code	2834

Key Executives

Name	Position
Shaun R. Bagai	Chief Executive Officer, Secretary and Director
Leesa Gentry	Chief Clinical Officer
Mark Voll	Chief Financial Officer and Principal Accounting Officer
Robert Strasser	Vice President of Operations and Research & Development
Ryan Witt	Senior Vice President and Head of Corporate Strategy and Partnerships
Ronald B. Kocak CPA, CGMA	Vice President of Finance and Controller

Latest SEC Filings

Date	Type	Title
Apr 9, 2026	D	Notice of Exempt Offering of Securities
Mar 31, 2026	S-8	Securities to be offered to employees in employee benefit plans
Mar 30, 2026	8-K	Current Report
Mar 30, 2026	10-K	Annual Report
Mar 27, 2026	8-K	Current Report
Mar 23, 2026	8-K	Current Report
Feb 6, 2026	8-K	Current Report
Jan 30, 2026	SCHEDULE 13G/A	Filing
Jan 2, 2026	8-K	Current Report
Nov 14, 2025	8-K	Current Report

View All SEC Filings